title: Measuring the Value of New Medications and Implications for Medicare's Proposed Part B Drug Payment Model.
authors.affiliation: Faculty of Arts and Sciences, Harvard University, Boston, Massachusetts2Brigham and Women's Hospital, Boston, Massachusetts.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Hwang
authors.affiliation: PureTech, Boston, Massachusetts.
authors.forename: John L
authors.initials: JL
authors.lastname: LaMattina
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D016527:Drug Costs; D005102:Health Expenditures; D006291:Health Policy / Q000191:economics*; D006801:Humans; D016345:Medicare Part B / Q000191:economics*; D009369:Neoplasms / Q000188:drug therapy*; D004364:Pharmaceutical Preparations / Q000191:economics; D012051:Reimbursement Mechanisms; D014481:United States; D062505:Value-Based Purchasing
chemical_list: D000970:Antineoplastic Agents; D004364:Pharmaceutical Preparations